Bio-Rad Laboratories, Inc. Peer Comparison
Metric | Value | Ranking | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | $7.9 Billion | 9/17 | DXCM $34.8B |
STE $21.6B |
ZBH $20.0B |
PODD $19.7B |
SWAV $12.6B |
GMED $11.4B |
PEN $10.3B |
GKOS $8.4B |
BIO $7.9B |
BRKR $7.6B |
INSP $5.5B |
ITGR $4.7B |
NARI $4.7B |
NVCR $2.4B |
TNDM $2.2B |
CNMD $2.0B |
ANIK $261.6M |
Gross Margin | 55% | 11/17 | PODD 100% |
SWAV 87% |
NARI 87% |
INSP 85% |
GKOS 77% |
NVCR 77% |
PEN 67% |
DXCM 60% |
GMED 57% |
CNMD 57% |
BIO 55% |
BRKR 47% |
STE 45% |
TNDM 34% |
ITGR 16% |
ANIK 4% |
ZBH 0% |
Profit Margin | 100% | 1/17 | BIO 100% |
SWAV 25% |
PODD 21% |
CNMD 15% |
INSP 15% |
DXCM 14% |
STE 13% |
PEN 10% |
GMED 8% |
BRKR 5% |
ITGR 5% |
ZBH 0% |
TNDM -6% |
NARI -12% |
NVCR -20% |
GKOS -22% |
ANIK -77% |
EBITDA margin | 214% | 1/17 | BIO 214% |
PODD 24% |
INSP 24% |
CNMD 21% |
SWAV 19% |
STE 18% |
DXCM 15% |
PEN 15% |
GMED 8% |
ITGR 8% |
NARI -5% |
TNDM -7% |
BRKR -9% |
NVCR -21% |
GKOS -26% |
ANIK -66% |
ZBH -100% |
Quarterly Revenue | $649.7 Million | 5/17 | STE $1.4B |
DXCM $994.2M |
BRKR $864.4M |
ITGR $746.3M |
BIO $649.7M |
GMED $625.7M |
PODD $372.6M |
TNDM $363.3M |
CNMD $316.7M |
PEN $301.0M |
INSP $239.7M |
SWAV $218.8M |
NVCR $155.1M |
NARI $153.4M |
GKOS $96.7M |
ANIK $38.8M |
ZBH $0 |
Quarterly Earnings | $653.2 Million | 1/17 | BIO $653.2M |
STE $173.5M |
DXCM $134.6M |
PODD $77.5M |
SWAV $55.3M |
GMED $51.8M |
CNMD $49.0M |
BRKR $40.9M |
ITGR $35.4M |
INSP $35.2M |
PEN $29.5M |
ZBH -$0 |
NARI -$18.4M |
GKOS -$21.4M |
TNDM -$23.3M |
ANIK -$29.9M |
NVCR -$30.6M |
Quarterly Free Cash Flow | $246.7 Million | 1/17 | BIO $246.7M |
STE $243.6M |
GMED $161.7M |
ITGR $131.8M |
DXCM $88.3M |
PODD $76.1M |
INSP $62.2M |
PEN $51.0M |
CNMD $47.8M |
SWAV $27.5M |
TNDM $21.5M |
BRKR $5.8M |
ANIK $3.8M |
NVCR -$307,000 |
NARI -$995,000 |
GKOS -$11.0M |
ZBH -$0 |
Trailing 4 Quarters Revenue | $2.7 Trillion | 1/17 | BIO $2.7T |
ZBH $5.7B |
STE $5.4B |
DXCM $4.0B |
BRKR $3.2B |
GMED $2.5B |
ITGR $2.0B |
PODD $1.8B |
CNMD $1.3B |
PEN $1.2B |
TNDM $973.7M |
INSP $802.8M |
SWAV $788.0M |
NVCR $577.7M |
NARI $574.5M |
GKOS $360.3M |
ANIK $164.2M |
Trailing 4 Quarters Earnings | -$637.5 Billion | 17/17 | STE $1.4B |
DXCM $994.2M |
BRKR $864.4M |
ITGR $746.3M |
BIO $649.7M |
GMED $625.7M |
PODD $372.6M |
TNDM $363.3M |
CNMD $316.7M |
PEN $301.0M |
INSP $239.7M |
SWAV $218.8M |
NVCR $155.1M |
NARI $153.4M |
GKOS $96.7M |
ANIK $38.8M |
ZBH -$0 |
Quarterly Earnings Growth | 515% | 2/17 | GMED 5094% |
BIO 515% |
PEN 220% |
CNMD 209% |
INSP 139% |
PODD 49% |
SWAV 41% |
NVCR 38% |
GKOS 30% |
ITGR 30% |
TNDM 29% |
STE 23% |
DXCM 12% |
ZBH 0% |
BRKR -54% |
ANIK -355% |
NARI -681% |
Annual Earnings Growth | -18757% | 17/17 | INSP 593% |
PODD 215% |
CNMD 131% |
DXCM 45% |
ZBH 36% |
NVCR 32% |
BRKR 18% |
ITGR 15% |
TNDM 10% |
STE -4% |
GKOS -16% |
GMED -47% |
PEN -48% |
SWAV -65% |
ANIK -559% |
NARI -934% |
BIO -18757% |
Quarterly Revenue Growth | 3% | 12/17 | TNDM 96% |
GMED 63% |
SWAV 36% |
INSP 25% |
GKOS 24% |
NVCR 22% |
NARI 21% |
BRKR 16% |
PEN 11% |
ITGR 6% |
CNMD 4% |
BIO 3% |
DXCM 2% |
STE -2% |
ANIK -7% |
PODD -14% |
ZBH -100% |
Annual Revenue Growth | 99740% | 1/17 | BIO 99740% |
GMED 97% |
SWAV 33% |
TNDM 26% |
INSP 23% |
NARI 19% |
BRKR 16% |
NVCR 14% |
GKOS 13% |
PODD 12% |
DXCM 10% |
PEN 10% |
ITGR 6% |
ZBH 4% |
CNMD 2% |
STE 0% |
ANIK -6% |
Cash On Hand | $410.4 Million | 5/17 | PODD $902.6M |
GMED $622.8M |
DXCM $621.2M |
ZBH $525.5M |
BIO $410.4M |
SWAV $281.7M |
PEN $280.5M |
STE $155.2M |
INSP $150.2M |
BRKR $148.1M |
GKOS $100.1M |
ANIK $62.4M |
TNDM $49.0M |
NARI $41.1M |
CNMD $38.5M |
ITGR $35.6M |
NVCR -$0 |
Short Term Debt | $1.3 Million | 14/17 | ZBH $863.0M |
STE $125.0M |
NVCR $86.4M |
PODD $42.0M |
BRKR $32.8M |
DXCM $22.3M |
TNDM $18.0M |
PEN $14.5M |
ITGR $13.9M |
GMED $11.0M |
SWAV $3.7M |
ANIK $2.3M |
NARI $1.6M |
BIO $1.3M |
CNMD $717,000 |
GKOS -$0 |
INSP -$0 |
Long Term Debt | $1.2 Billion | 5/17 | ZBH $5.3B |
DXCM $2.5B |
BRKR $2.3B |
PODD $1.4B |
BIO $1.2B |
ITGR $1.2B |
CNMD $940.1M |
SWAV $773.1M |
GMED $523.5M |
TNDM $457.9M |
PEN $212.2M |
GKOS $157.1M |
STE $123.7M |
NARI $31.1M |
INSP $30.0M |
ANIK $25.2M |
NVCR $0 |
PE | -1.00 | 12/17 | PEN 298.47 |
GMED 124.88 |
INSP 102.92 |
SWAV 76.87 |
DXCM 51.10 |
PODD 46.76 |
STE 46.09 |
ITGR 41.65 |
ZBH 30.12 |
BRKR 24.88 |
CNMD 14.81 |
BIO -1.00 |
GKOS -1.00 |
TNDM -1.00 |
NVCR -1.00 |
ANIK -1.00 |
NARI -1.00 |
PS | 0.00 | 17/17 | GKOS 23.44 |
SWAV 15.95 |
PODD 10.86 |
PEN 8.86 |
DXCM 8.80 |
NARI 8.15 |
INSP 6.86 |
GMED 4.61 |
NVCR 4.21 |
STE 3.99 |
ZBH 3.54 |
ITGR 2.35 |
BRKR 2.34 |
TNDM 2.26 |
ANIK 1.59 |
CNMD 1.51 |
BIO 0.00 |
PB | 1.06 | 16/17 | PODD 17.60 |
DXCM 17.58 |
SWAV 16.72 |
GKOS 12.64 |
NARI 10.77 |
PEN 9.34 |
TNDM 9.25 |
INSP 7.98 |
BRKR 4.12 |
STE 3.35 |
ITGR 2.92 |
GMED 2.81 |
CNMD 2.09 |
ANIK 1.45 |
ZBH 1.39 |
BIO 1.06 |
NVCR 0.00 |
PC | 19.34 | 14/17 | STE 138.87 |
ITGR 132.95 |
NARI 113.78 |
GKOS 84.35 |
DXCM 56.00 |
BRKR 51.22 |
CNMD 50.71 |
TNDM 44.83 |
SWAV 44.62 |
ZBH 38.08 |
PEN 36.76 |
INSP 36.68 |
PODD 21.80 |
BIO 19.34 |
GMED 18.35 |
ANIK 4.19 |
NVCR -1.00 |
Liabilities to Equity | 0.42 | 12/17 | TNDM 3.03 |
NVCR 2.39 |
BRKR 2.34 |
DXCM 2.21 |
PODD 1.71 |
CNMD 1.48 |
SWAV 1.19 |
ITGR 0.95 |
NARI 0.60 |
STE 0.56 |
ZBH 0.48 |
BIO 0.42 |
GKOS 0.39 |
PEN 0.34 |
ANIK 0.29 |
GMED 0.25 |
INSP 0.17 |
ROA | -60.12 | 17/17 | PODD 14% | DXCM 11% | SWAV 10% | INSP 7% | CNMD 6% | BRKR 5% | STE 5% | ITGR 4% | ZBH 3% | GMED 2% | PEN 2% | NARI -11% | TNDM -13% | GKOS -16% | ANIK -42% | NVCR -100% | BIO -6012% |
ROE | -85.13 | 17/17 | PODD 38% |
DXCM 34% |
SWAV 22% |
BRKR 17% |
CNMD 14% |
INSP 8% |
STE 7% |
ITGR 7% |
ZBH 5% |
PEN 3% |
GMED 2% |
NARI -18% |
GKOS -22% |
NVCR -42% |
TNDM -53% |
ANIK -54% |
BIO -8513% |
Current Ratio | 3.40 | 6/17 | INSP 6.81 |
GMED 5.00 |
ANIK 4.49 |
PEN 3.95 |
GKOS 3.59 |
BIO 3.40 |
ZBH 3.08 |
STE 2.80 |
NARI 2.66 |
ITGR 2.05 |
SWAV 1.84 |
CNMD 1.67 |
PODD 1.59 |
DXCM 1.45 |
BRKR 1.43 |
TNDM 1.33 |
NVCR 0.00 |
Quick Ratio | 0.52 | 9/17 | PEN 298.47 |
GMED 124.88 |
INSP 102.92 |
SWAV 76.87 |
DXCM 51.10 |
PODD 46.76 |
STE 46.09 |
ITGR 41.65 |
ZBH 30.12 |
BRKR 24.88 |
CNMD 14.81 |
BIO -1.00 |
GKOS -1.00 |
TNDM -1.00 |
NVCR -1.00 |
ANIK -1.00 |
NARI -1.00 |
Long Term Debt to Equity | 0.16 | 11/17 | TNDM} 1.93 |
DXCM} 1.27 |
BRKR} 1.24 |
PODD} 1.21 |
SWAV} 1.03 |
CNMD} 1.01 |
ITGR} 0.71 |
ZBH} 0.37 |
GKOS} 0.24 |
PEN} 0.19 |
BIO} 0.16 |
ANIK} 0.14 |
GMED} 0.13 |
NARI} 0.07 |
INSP} 0.04 |
STE} 0.02 |
NVCR} 0.00 |
Debt to Equity | 0.16 | 12/17 | TNDM 2.00 |
DXCM 1.28 |
BRKR 1.26 |
PODD 1.25 |
SWAV 1.03 |
CNMD 1.01 |
ITGR 0.72 |
ZBH 0.43 |
GKOS 0.24 |
NVCR 0.24 |
PEN 0.21 |
BIO 0.16 |
GMED 0.13 |
NARI 0.08 |
INSP 0.04 |
STE 0.02 |
ANIK 0.01 |
Burn Rate | -0.68 | 8/17 | GKOS 3.62 |
BRKR 2.56 |
ITGR 2.48 |
NARI 2.06 |
ANIK 1.98 |
TNDM 1.06 |
NVCR 0.00 |
BIO -0.68 |
ZBH -1.00 |
STE -1.13 |
CNMD -3.43 |
INSP -4.41 |
SWAV -11.98 |
PEN -16.10 |
DXCM -21.72 |
GMED -22.13 |
PODD -70.80 |
Cash to Cap | 0.05 | 2/17 | ANIK 0.24 |
BIO 0.05 |
PODD 0.05 |
GMED 0.05 |
ZBH 0.03 |
PEN 0.03 |
INSP 0.03 |
TNDM 0.02 |
DXCM 0.02 |
BRKR 0.02 |
CNMD 0.02 |
SWAV 0.02 |
GKOS 0.01 |
STE 0.01 |
ITGR 0.01 |
NARI 0.01 |
NVCR 0.00 |
CCR | 0.38 | 11/17 | ITGR 3.72 |
GMED 3.12 |
INSP 1.76 |
PEN 1.73 |
STE 1.40 |
PODD 0.98 |
CNMD 0.98 |
DXCM 0.66 |
GKOS 0.52 |
SWAV 0.50 |
BIO 0.38 |
BRKR 0.14 |
NARI 0.05 |
NVCR 0.01 |
ANIK -0.13 |
TNDM -0.93 |
ZBH |
EV to EBITDA | 6.28 | 10/17 | SWAV} 308.03 |
DXCM} 241.46 |
GMED} 235.78 |
PEN} 231.75 |
PODD} 229.01 |
ITGR} 101.10 |
INSP} 94.92 |
STE} 87.73 |
CNMD} 43.42 |
BIO} 6.28 |
ZBH} -1.00 |
ANIK} -7.88 |
NVCR} -78.48 |
TNDM} -100.61 |
BRKR} -126.60 |
GKOS} -344.85 |
NARI} -648.07 |
EV to Revenue | 0.00 | 16/17 | GKOS 23.60 |
SWAV 16.58 |
PODD 11.13 |
DXCM 9.28 |
PEN 8.81 |
NARI 8.13 |
INSP 6.71 |
GMED 4.58 |
NVCR 4.36 |
STE 3.99 |
BRKR 3.00 |
ITGR 2.92 |
TNDM 2.70 |
CNMD 2.21 |
ANIK 1.23 |
BIO 0.00 |
ZBH -1.00 |